Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... co-infected patients who are not also receiving highly active antiretroviral therapy (HAART). Before initiating BARACLUDE therapy, HIV antibody testing should be offered to all ...
2009 NOV 23 ... documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year longitudinal study of the MANIF 2000 cohort of ...
2009 NOV 9 ... of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression. Jaids - Journal of Acquired Immune Deficiency ...
2009 NOV 9 ... implicated as a factor in nonadherence to highly active antiretroviral therapy (HAART). There have not been efforts to systematically evaluate findings across studies." ...
2009 NOV 9 ... from Haikou, People's Republic of China, "Highly active anti-retroviral therapy (HAART) is the current HIV/AIDS treatment modality. Despite the fact that...
2009 NOV 23 ... risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART' have been presented. According to recent research from the United States, "The ...
2009 NOV 9 ... hepatitis C virus (HCV). He had been treated with highly active antiretroviral therapy (HAART) since 1990," wrote R.V. Dinavahi and colleagues. The researchers ...
2009 NOV 9 ... life-long virus persistence, even after long-term highly active antiretroviral therapy (HAART). The role that latency is playing in preventing clearance of the virus infection has ...
2009 NOV 9 ... IL-2 is currently used as a complement to highly active antiretroviral therapy (known as HAART), which is administered to patients with HIV-AIDS. Since...
2009 NOV 16 ... guyanensis. Three months after initiation of highly active anti-retroviral therapy (HAART), the patient had disseminated cutaneous leishmaniasis and started anti-leishmanial ...
2009 NOV 2 ... who achieve viral loads of <50 copies/ml during highly active antiretroviral therapy (HAART), low levels of plasma virus remain detectable for years by ultrasensitive methods. The ...
2009 NOV 2 ... well-defined subgroups of HIV-infected individuals both before (n=62) and during HAART (n=40) as well as in age-and sex-matched healthy controls (n=30). We also examined the ...
2009 NOV 9 ... 95% confidence interval [CI] 0.34, 1.02) and highly active antiretroviral therapy (HAART) use during TB therapy (RR 0.37, 95% CI 0.13, 1.02) were independently associated with ...
2009 NOV 9 ... before and at two times after introduction of highly active anti-retroviral therapy (HAART), were tested for TTV load and the presence of the five highly divergent TTV ...
2009 NOV 2 ... analyses. 156 cases of PHI were included, of which 100 had received transient HAART (median treatment time 9.5 months) and 56 remained untreated. Median viral load (563000 ...
2009 NOV 9 ... markets are discussed along with unmet needs that have evolved from the prolonged use of HAART Sales forecasts over the next 10 years for the each of the late-stage drugs ...
2009 NOV 2 ... in both the groups (5.9 vs 5.8 log IU/mL). Overall, 78.8% of the HIV patients were on HAART and their mean CD4 count was 525 (+/-278) cells/microL. In HIV-negatives, liver fibrosis ...
2009 NOV 9 ... The researchers concluded: "Remarkably, 26 of 47 (55%) patients under HAART with detectable virus loads did not have any known drug-resistant mutation, indicating ...
2009 NOV 23 ... Pseudomonas aeruginosa in the subgingival biofilm of HIV-infected subjects undergoing HAART with chronic periodontitis.' "This study compared the frequency of Helicobacter ...
2009 NOV 16 ... patients with HIV infection. We will be treating patients currently well-controlled on HAART therapies in order to establish whether the engineered killer T cells containing the ...
